Stock Track | Vericel Plummets 5.11% After Missing Q4 Sales Estimates

Stock Track

Feb 28

Vericel Corporation (NASDAQ: VCEL) shares plummeted 5.11% in the intraday trading session on Thursday, despite the company reporting better-than-expected earnings for the fourth quarter of 2024.

The biopharmaceutical company reported quarterly earnings of $0.38 per share, surpassing the analyst consensus estimate of $0.32 by 18.75%. However, Vericel's quarterly sales of $75.38 million missed the analyst consensus estimate of $76.47 million by 1.43%, which may have contributed to the stock's decline.

While Vericel's earnings exceeded expectations, the company's sales miss suggests that its revenue growth may have fallen short of analysts' projections. Investors often closely monitor a company's revenue performance as it can be an indicator of future earnings potential and growth prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1128818563"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128818563\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128818563?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 03:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128818563","market":"hk","top_or_hot":-1,"title":"Stock Track | Vericel Plummets 5.11% After Missing Q4 Sales Estimates","media":"Stock Track","content":"<p>Vericel Corporation (NASDAQ: VCEL) shares plummeted 5.11% in the intraday trading session on Thursday, despite the company reporting better-than-expected earnings for the fourth quarter of 2024.</p>\n\n<p>The biopharmaceutical company reported quarterly earnings of $0.38 per share, surpassing the analyst consensus estimate of $0.32 by 18.75%. However, Vericel's quarterly sales of $75.38 million missed the analyst consensus estimate of $76.47 million by 1.43%, which may have contributed to the stock's decline.</p>\n\n<p>While Vericel's earnings exceeded expectations, the company's sales miss suggests that its revenue growth may have fallen short of analysts' projections. Investors often closely monitor a company's revenue performance as it can be an indicator of future earnings potential and growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Vericel Plummets 5.11% After Missing Q4 Sales Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Vericel Plummets 5.11% After Missing Q4 Sales Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-28 03:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vericel Corporation (NASDAQ: VCEL) shares plummeted 5.11% in the intraday trading session on Thursday, despite the company reporting better-than-expected earnings for the fourth quarter of 2024.</p>\n\n<p>The biopharmaceutical company reported quarterly earnings of $0.38 per share, surpassing the analyst consensus estimate of $0.32 by 18.75%. However, Vericel's quarterly sales of $75.38 million missed the analyst consensus estimate of $76.47 million by 1.43%, which may have contributed to the stock's decline.</p>\n\n<p>While Vericel's earnings exceeded expectations, the company's sales miss suggests that its revenue growth may have fallen short of analysts' projections. Investors often closely monitor a company's revenue performance as it can be an indicator of future earnings potential and growth prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VCEL","symbol_name":"Vericel Corporation","start_time":0,"source_url":"","article_id":"1128818563","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128818563","pubTimestamp":1740682951,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Vericel Corporation  shares plummeted 5.11% in the intraday trading session on Thursday, despite the company reporting better-than-expected earnings for the fourth quarter of 2024.The biopharmaceutical company reported quarterly earnings of $0.38 per share, surpassing the analyst consensus estimate of $0.32 by 18.75%. However, Vericel's quarterly sales of $75.38 million missed the analyst consensus estimate of $76.47 million by 1.43%, which may have contributed to the stock's decline.While Veric","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VCEL":"Vericel Corporation"},"translate_title":"股票跟踪Vericel在未达到第四季度销售预期后暴跌5.11%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCEL":1},"content_text":"Vericel Corporation (NASDAQ: VCEL) shares plummeted 5.11% in the intraday trading session on Thursday, despite the company reporting better-than-expected earnings for the fourth quarter of 2024.\nThe biopharmaceutical company reported quarterly earnings of $0.38 per share, surpassing the analyst consensus estimate of $0.32 by 18.75%. However, Vericel's quarterly sales of $75.38 million missed the analyst consensus estimate of $76.47 million by 1.43%, which may have contributed to the stock's decline.\nWhile Vericel's earnings exceeded expectations, the company's sales miss suggests that its revenue growth may have fallen short of analysts' projections. Investors often closely monitor a company's revenue performance as it can be an indicator of future earnings potential and growth prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}